Single-center, open-label, phase I study to investigate the pharmacokinetics (PK), tolerability, and safety of a single oral dose of macitentan in subjects with severe renal function impairment.

Trial Profile

Single-center, open-label, phase I study to investigate the pharmacokinetics (PK), tolerability, and safety of a single oral dose of macitentan in subjects with severe renal function impairment.

Completed
Phase of Trial: Phase I

Latest Information Update: 14 Aug 2014

At a glance

  • Drugs Macitentan (Primary)
  • Indications Eisenmenger complex; Glioblastoma; Idiopathic pulmonary fibrosis; Pulmonary arterial hypertension; Skin ulcer
  • Focus Pharmacokinetics
  • Sponsors Actelion Pharmaceuticals
  • Most Recent Events

    • 14 Aug 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top